Skip to main content

by Dr. C.H. Weaver M.D. updated 12/2020

DPX-Survivac—an investigational vaccine designed to prompt an immune response against cancer cells—will undergo Phase I/II testing in patients with ovarian cancer. This announcement was made by one of the companies involved in developing the vaccine.

DPX-Survivac is an investigational anticancer vaccine. The vaccine is designed to prompt the body’s immune system to recognize and attack cancer cells. The specific characteristics of ovarian cancer make it a promising target for this vaccine. DPX-Survivac works by stimulating the immune system to target and destroy cancer cells. Specifically, it targets cancer cells that carry survivin on their surface, a protein known to promote tumor growth. The immunotherapy, composed of small fractions of the survivin protein, is delivered as an under-the-skin injection to trigger a durable activation of T-cells (immune cells with the ability to fight cancers) against survivin-positive cancers.

DPX-Survivac plus low-dose chemotherapy shows sustained benefits in people with heavily treated advanced ovarian cancer, with some benefits lasting up to 16 months.

The DECIDE1 trial (NCT02785250) is evaluating a combination of DPX-Survivac plus low-dose intermittent cyclophosphamide to treat women whose ovarian cancer came back after surgery and treatment with at least one chemotherapy regimen are ongoing.

Scroll to Continue

Recommended Articles


  1. Immunovaccine Media Release. Immunovaccine Inc. announces Phase I/II Clinical Plan for DPX-Survivac to target Ovarian Cancer. November 17, 2010.
  2. IMV’s Survivin-Targeted T Cell Therapy Shows Durable Clinical Benefits in Phase 2 Study in Patients with Hard-to-Treat Advanced Recurrent Ovarian Cancer